Evidence map›Paper›PMID 41022837›Full record

ArticleScientific reports2025

A quantitative high-throughput screening pipeline to identify small molecule inhibitors of Chikungunya nsP2 protease.

Shuaizhang Li, Xin Hu, Yong-Mo Ahn, Angelica Medina, Lin Ye, Audrey Heffner, Simon Messing, John-Paul Denson, Dominic Esposito, Emily M Lee and 1 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Proteomic Analysis of Influenza.Advances in experimental medicine and biology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shuaizhang LiNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
Xin HuNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
Yong-Mo AhnNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
Angelica MedinaNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
Lin YeNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
Audrey HeffnerNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
Simon MessingProtein Expression Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
John-Paul DensonProtein Expression Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Dominic EspositoProtein Expression Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Emily M LeeNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
Natalia J MartinezNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA. natalia.martinez@nih.gov.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chikungunya virus (CHIKV) is a mosquito-borne RNA virus that has emerged as one of the most important global arboviral threats in the last decade. Although the first CHIKV vaccine has recently been FDA approved for use in healthy adults at increased risk, to date, there are no available antiviral drugs for CHIKV infection. CHIKV nsP2 protease plays a crucial role in the processing of the viral polypeptide precursor to release enzymes required for viral replication, thus making it a promising drug target for antiviral discovery. Here, we established a high-throughput pipeline to identify small molecule inhibitors of nsP2 proteolytic activity. The pipeline is composed of a suite of 1,536-well in vitro assays to support quantitative high-throughput (qHTS) screening campaigns. Specifically, we developed a fluorescence resonance energy transfer (FRET)-based assay using a fluorogenic peptide substrate encompassing an endogenous cleavage site and purified recombinant protease domain (nsP2pro). Using this assay, we interrogated ~ 31,000 unique small molecules, including those in drug repurposing libraries as well as chemically diverse and medicinal chemistry-friendly compounds. Hits were selected for follow-up validation against full-length nsP2 and an additional peptide. FRET-based 1,536-well assays for Papain, hepatitis C virus NS3-4A, and human Furin proteases were implemented to characterize compound selectivity. Notably, we developed a high-throughput cell-based proteolytic assay using a split nanoluciferase reporter to identify cell-active hits. Novel compounds were found to be potential nsP2 inhibitors and molecular docking analyses were performed to explain the binding mode of selected hits. In vitro antiviral activity was evaluated for a subset of compounds using a high-throughput CHIKV infection assay. To our knowledge, the pipeline presented here is unprecedented for CHIKV antiviral discovery research.

Indexed as

Antiviral AgentsChikungunya virusCysteine EndopeptidasesHigh-Throughput Screening AssaysProtease InhibitorsSmall Molecule LibrariesChikungunya FeverDrug DiscoveryFluorescence Resonance Energy TransferHumansMolecular Docking SimulationVirus ReplicationAntiviral AgentsCysteine EndopeptidasesnsP2 proteinaseProtease InhibitorsSmall Molecule LibrariesChikungunya virusCHIKVDrug repurposingnsP2 proteaseqHTS

Identifiers

PMID41022837
PMCPMC12480751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.